Patents by Inventor Lena A. BASILE

Lena A. BASILE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240181010
    Abstract: Aspects and embodiments of the present disclosure provide therapeutic methods comprising interleukin 12 (IL-12) as a replacement immunotherapeutic. The method comprises administering a physiological dose of exogenous IL-12 to a subject.
    Type: Application
    Filed: July 18, 2017
    Publication date: June 6, 2024
    Inventor: Lena A. BASILE
  • Publication number: 20220168393
    Abstract: Aspects and embodiments of the instant disclosure provide therapeutic methods and compositions comprising interleukin 12 (IL-12) useful for improving hematopoietic recovery HSCT transplantation in a subject. In particular, the instant disclosure provide exemplary methods and compositions comprising IL-12 promoted hematopoiesis and increased the recovery of peripheral blood cells and survival in lethally irradiated mice as effectively as a BMCT, indicating that rHuIL-12 therapy can to increase HSC engraftment following HSCT. We identified IL-12R?2 expressing cells in irradiated mouse bone marrow which are potential targets of IL-12. Administration of rMuIL-12 increased the number of IL-12R?2 expressing Lin? cells in mouse bone marrow, indicating that bone marrow HSCs and niche cells are the direct target of rMuIL-12 and that hematopoiesis-promoting activity of rMuIL-12 is mediated by IL-12 receptors on HSCs.
    Type: Application
    Filed: July 6, 2021
    Publication date: June 2, 2022
    Inventor: Lena A. BASILE
  • Publication number: 20200030412
    Abstract: Aspects and embodiments of the instant disclosure provide therapeutic methods and compositions comprising interleukin 12 (IL-12) useful for improving hematopoietic recovery HSCT transplantation in a subject. In particular, the instant disclosure provide exemplary methods and compositions comprising IL-12 promoted hematopoiesis and increased the recovery of peripheral blood cells and survival in lethally irradiated mice as effectively as a BMCT, indicating that rHuIL-12 therapy can to increase HSC engraftment following HSCT. We identified IL-12R?2 expressing cells in irradiated mouse bone marrow which are potential targets of IL-12. Administration of rMuIL-12 increased the number of IL-12R?2 expressing Lin? cells in mouse bone marrow, indicating that bone marrow HSCs and niche cells are the direct target of rMuIL-12 and that hematopoiesis-promoting activity of rMuIL-12 is mediated by IL-12 receptors on HSCs.
    Type: Application
    Filed: March 4, 2019
    Publication date: January 30, 2020
    Inventor: Lena A. BASILE
  • Publication number: 20160120949
    Abstract: Aspects and embodiments of the instant disclosure provide therapeutic methods and compositions comprising interleukin 12 (IL-12) as a hematopoietic immunotherapy (HIT) useful for treating or preventing a cancer patient from chemotherapy-induced cytopenias necessitating a dose reduction and/or dose delay. following exposure of the patient to chemotherapeutic agents, the method comprising: administering a dose of therapeutically effective amount of a pharmaceutical composition comprising substantially isolated IL-12 to the subject, whereby cytopenias are reduced and leading to increases responses to the chemotherapy agent(s).diminished.
    Type: Application
    Filed: October 30, 2015
    Publication date: May 5, 2016
    Applicant: NEUMEDICINES, INC.
    Inventor: Lena A. BASILE
  • Publication number: 20160120948
    Abstract: Aspects and embodiments of the instant disclosure provide therapeutic methods and compositions comprising interleukin 12 (IL-12) useful for improving hematopoietic recovery HSCT transplantation in a subject. In particular, the instant disclosure provide exemplary methods and compositions comprising IL-12 promoted hematopoiesis and increased the recovery of peripheral blood cells and survival in lethally irradiated mice as effectively as a BMCT, indicating that rHuIL-12 therapy can to increase HSC engraftment following HSCT. We identified IL-12R?2 expressing cells in irradiated mouse bone marrow which are potential targets of IL-12. Administration of rMuIL-12 increased the number of IL-12R?2 expressing Lin? cells in mouse bone marrow, indicating that bone marrow HSCs and niche cells are the direct target of rMuIL-12 and that hematopoiesis-promoting activity of rMuIL-12 is mediated by IL-12 receptors on HSCs.
    Type: Application
    Filed: October 30, 2015
    Publication date: May 5, 2016
    Applicant: Neumedicines, Inc.
    Inventor: Lena A. BASILE
  • Publication number: 20150110739
    Abstract: The present application relates to stem cells isolated from various sources within the body of a patient or of a healthy donor and identified by the presence of the interleukin 12 (IL-12) receptor. The present application also provides methods for making and for using the stem cells.
    Type: Application
    Filed: August 26, 2014
    Publication date: April 23, 2015
    Applicant: NEUMEDICINES, INC.
    Inventor: Lena A. BASILE
  • Publication number: 20140342995
    Abstract: The present invention is directed to methods of using HSS1 (Hematopoietic Signal peptide-containing Secreted 1), HSM1 (Hematopoietic Signal peptide-containing Membrane domain-containing 1), or a combination thereof in the treatment of various cancers, such as brain cancers.
    Type: Application
    Filed: April 14, 2014
    Publication date: November 20, 2014
    Applicant: Neumedicines, Inc.
    Inventor: Lena A. BASILE
  • Publication number: 20120189577
    Abstract: The present invention is directed to methods of increasing survival following exposure to non-therapeutic radiation comprising administration of IL-12.
    Type: Application
    Filed: January 18, 2012
    Publication date: July 26, 2012
    Inventor: Lena A. BASILE